We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Miscellaneous 0.16%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
101
Protara Therapeutics
TARA
$226M
$535K ﹤0.01%
199,671
– –
GTH
102
DELISTED
Genetron Holdings Limited ADS
GTH
$510K ﹤0.01%
151,769
– –
KZR
103
DELISTED
Kezar Life Sciences
KZR
$436K ﹤0.01%
6,195
– –
INSM icon
104
Insmed
INSM
$28.3B
$399K ﹤0.01%
19,950
– –
FHTX icon
105
Foghorn Therapeutics
FHTX
$262M
$287K ﹤0.01%
45,027
– –
SERA icon
106
Sera Prognostics
SERA
$80.1M
$254K ﹤0.01%
201,562
– –
CYPH
107
Cypherpunk Technologies Inc
CYPH
$278M
$252K ﹤0.01%
55,971
– –
VINC
108
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$246K ﹤0.01%
12,069
– –
BLCM
109
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$179K ﹤0.01%
249,123
– –
SRZNW
110
DELISTED
Surrozen Inc Warrant
SRZNW
$45.9K ﹤0.01%
833,333
– –
ATYR
111
aTyr Pharma
ATYR
$38.1M
$18.8K ﹤0.01%
8,565
-192,796
-96% -$455K
ALKS icon
112
Alkermes
ALKS
$7.71B
– –
-815,016
Closed -$18.2M
ALLK
113
DELISTED
Allakos
ALLK
– –
-703,050
Closed -$4.3M
AMRN
114
Amarin Corp
AMRN
$291M
– –
-268,856
Closed -$5.86M
CRNX
115
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-735,716
Closed -$14.4M
FLGT icon
116
Fulgent Genetics
FLGT
$563M
– –
-166,619
Closed -$6.35M
RLMD icon
117
Relmada Therapeutics
RLMD
$482M
– –
-495,113
Closed -$18.3M
SNDX icon
118
Syndax Pharmaceuticals
SNDX
$1.62B
– –
-110,729
Closed -$2.66M
SRZN icon
119
Surrozen
SRZN
$223M
– –
-166,667
Closed -$5.05M
EIGR
120
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-17,995
Closed -$4.07M
TCDA
121
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,320,290
Closed -$13.8M
OTIC
122
DELISTED
Otonomy, Inc.
OTIC
– –
-8,443,134
Closed -$2.49M
LOGC
123
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
– –
-139,105
Closed -$38K
CCXI
124
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-1,792,657
Closed -$92.6M
FMTX
125
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-1,886,760
Closed -$37.6M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Baker Bros. Advisors held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Baker Bros. Advisors added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Baker Bros. Advisors's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Baker Bros. Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Baker Bros. Advisors opened 13 new positions and closed 15 in Q4 2022.
  • Baker Bros. Advisors's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.